About Careers Internship MedBlog Contact us

Can Apixaban Be a Better Option Than Warfarin for Atrial Fibrillation Patients?

by Madhumathi Palaniappan on April 3, 2017 at 10:19 AM
Font : A-A+

Can Apixaban Be a Better Option Than Warfarin for Atrial Fibrillation Patients?

Atrial fibrillation can cause irregular heartbeats, may lead to blood clots, stroke, heart failure and other heart-related complications.

A recent analysis found atrial fibrillation patients to show a significantly reduced risk of dangerous bleeding in the brain, referred to as the intracranial hemorrhage, while taking apixaban drug when compared to patients who took warfarin.


The study, published online today in Blood, the Journal of the American Society of Hematology (ASH), also showed that taking aspirin increased the risk of intracranial hemorrhage, especially in older patients.

"Intracranial hemorrhage has high morbidity and high mortality and is the most severe and most feared complication among physicians prescribing oral anticoagulants," said Renato D. Lopes, MD, PhD, a cardiologist at Duke Clinical Research Institute, the study's lead author. "This study shows apixaban is a better option for oral anticoagulation than warfarin because it reduces stroke while substantially reducing intracranial hemorrhage."

Atrial fibrillation is a type of irregular heartbeat that affects between 2.7 and 6.1 million Americans, according to estimates from the Centers for Disease Control and Prevention. An erratic heartbeat can allow blood to pool in the heart, which can lead to the formation of a blood clot that travels through the bloodstream and blocks a blood vessel in the brain, causing a stroke. Patients with atrial fibrillation are five times more likely to experience a stroke compared to the general population.

Medical guidelines recommend the use of oral anticoagulant medications in patients with atrial fibrillation who are at high risk for stroke. These medications reduce the blood's clotting ability, which substantially lowers the risk of stroke, but also increases the risk of uncontrolled bleeding.

Intracranial hemorrhage is a rare, but serious complication of these medications, occurring in about 1 percent of patients prescribed anticoagulants for atrial fibrillation. This type of bleeding in the brain can occur spontaneously or after trauma (such as a fall); can cause a range of symptoms including headache, vomiting, seizures, and coma; and has been associated with a 30-day mortality rate of 50 percent.

Historically, warfarin, a vitamin-K antagonist, has been considered the standard of care for oral anticoagulation therapy, but warfarin requires careful management to ensure patients receive the proper dosing. Drugs in a class of newer anticoagulants known as non-vitamin K antagonist oral anticoagulants, or NOACs, are easier to manage and have been shown to be as effective as warfarin, leading to a surge in the use of NOACs in patients with atrial fibrillation and other conditions in recent years.

The new analysis is the first to compare apixaban, a NOAC, to traditional warfarin in terms of the risk for intracranial hemorrhage.

The trial enrolled more than 18,000 patients in North America, Latin America, Europe, and Asia. All patients had atrial fibrillation and at least one additional risk factor for stroke. Patients were randomized to each medicine; half received apixaban and half received warfarin. Outcomes were tracked for a median of 1.8 years.

Intracranial hemorrhage occurred at a rate of 0.80 percent per year in patients taking warfarin and 0.33 percent per year in patients taking apixaban, meaning that patients taking apixaban were 58 percent less likely to experience intracranial hemorrhage compared to those taking warfarin. The difference was even greater for patients experiencing trauma-related intracranial hemorrhage; patients taking apixaban were 75 percent less likely to experience trauma-related bleeding compared to those taking warfarin. The results were consistent across all types and locations of bleeding in the brain.

The vast majority of patients taking warfarin showed INR (International Normalized Ratio) values, a measure of clotting factors, in the target range or below the target range within about two weeks of experiencing intracranial hemorrhage, which suggests their warfarin dosage was properly or under-calibrated, respectively.

Among all patients, the highest risk for intracranial hemorrhage was seen in patients who were age 80 or older, were treated in Asia or Latin America, or had a previous stroke or mini-stroke. Taking concomitant aspirin at the start of the study was found to significantly increase the risk of intracranial hemorrhage. About 30 percent of patients with atrial fibrillation use aspirin. Aspirin is a blood thinner that prevents platelets from clumping together, but it is not an anticoagulant medication and is not considered to effectively prevent strokes in patients with atrial fibrillation.

"We know that aspirin has only a modest effect in preventing stroke in atrial fibrillation patients, yet it was one of the top predictors of intracranial hemorrhage," said Dr. Lopes. "Our finding demonstrates that aspirin is not as safe as one might think." The increased risk of intracranial hemorrhage associated with aspirin use was particularly pronounced in older patients.

Future studies could help elucidate how the development and availability of antidotes for NOACs may affect the treatment and associated outcomes of intracranial hemorrhage, said Lopes.

Source: Eurekalert

News A-Z
What's New on Medindia
Alarming Cesarean Section Trends in India - Convenience or Compulsion of Corporate Healthcare
Quiz on Low-Calorie Diet for Diabetes
World Heart Day in 2022- Use Heart for Every Heart
View all
Recommended Reading
News Archive
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Palpitations And Arrhythmias Amyotrophic Lateral Sclerosis (ALS) Anticoagulants Deep Vein Thrombosis Pulmonary Embolism Atrial Fibrillation Cardiac Ablation Drugs for Atrial Fibrillation 

Most Popular on Medindia

Color Blindness Calculator Sinopril (2mg) (Lacidipine) Find a Hospital A-Z Drug Brands in India Indian Medical Journals Find a Doctor The Essence of Yoga Post-Nasal Drip Selfie Addiction Calculator Drug Side Effects Calculator
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use
open close


Can Apixaban Be a Better Option Than Warfarin for Atrial Fibrillation Patients? Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests